The peptide regulatory landscape moves faster than most coverage of it. FDA guidance shifts, compounding pharmacy access changes, enforcement actions land — and most of the impact gets buried in language designed for lawyers rather than readers.
Status: forthcoming
Our Regulatory Watch desk is in development. The first monthly "What Changed This Month in Peptides" briefing ships in the coming weeks, alongside the first standalone regulatory alerts.
What to expect
Every Regulatory Watch piece will follow the same structure:
- What changed — the specific regulatory development
- Why it matters — the practical stakes for users, vendors, and clinicians
- Who is affected — the specific subset of the market this touches
- What remains unclear — the ambiguities that survived the announcement
- What to watch next — the downstream consequences we're tracking
- Bottom line — the plain-English takeaway
We track:
- FDA notices and warning letters
- Compounding-related guidance (the one that keeps changing)
- Shortage status changes
- Enforcement actions
- State-level peptide policy developments
- Telehealth and prescribing-related regulatory changes
Foundational reading
- Are Peptides Legal in 2026? — the current legal landscape, explained.
- Methodology — how we evaluate regulatory content.